Gocher-Demske, Angela M.
Cui, Jian
Szymczak-Workman, Andrea L.
Vignali, Kate M.
Latini, Julianna N.
Pieklo, Gwen P.
Kimball, Jesse C.
Avery, Lyndsay http://orcid.org/0000-0002-8148-1648
Cipolla, Ellyse M.
Huckestein, Brydie R.
Hedden, Lee
Meisel, Marlies http://orcid.org/0000-0001-5156-8067
Alcorn, John F. http://orcid.org/0000-0001-5997-7711
Kane, Lawrence P. http://orcid.org/0000-0001-5198-516X
Workman, Creg J. http://orcid.org/0000-0002-9964-9509
Vignali, Dario A. A. http://orcid.org/0000-0002-2771-5992
Article History
Received: 2 December 2021
Accepted: 6 February 2023
First Online: 16 March 2023
Competing interests
: D.A.A.V. is a cofounder and stockholder for Novasenta, Potenza, Tizona and Trishula, is a stockholder for Oncorus, Werewolf and Apeximmune, holds patents licensed and royalties in BMS and Novasenta, serves on a scientific advisory board for Tizona, Werewolf, F-Star, Bicara, Apeximmune and T7/Imreg Bio and is a consultant for BMS, Incyte, G1 Therapeutics, Inzen Therapeutics, Regeneron and Avidity Partners. All the other authors declare no competing interests.